A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder

J Clin Invest. 1999 Feb;103(4):497-505. doi: 10.1172/JCI5542.

Abstract

Inherited defects in the degradation of glycosphingolipids (GSLs) cause a group of severe diseases known as GSL storage disorders. There are currently no effective treatments for the majority of these disorders. We have explored a new treatment paradigm, substrate deprivation therapy, by constructing a genetic model in mice. Sandhoff's disease mice, which abnormally accumulate GSLs, were bred with mice that were blocked in their synthesis of GSLs. The mice with simultaneous defects in GSL synthesis and degradation no longer accumulated GSLs, had improved neurologic function, and had a much longer life span. However, these mice eventually developed a late-onset neurologic disease because of accumulation of another class of substrate, oligosaccharides. The results support the validity of the substrate deprivation therapy and also highlight some limitations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Behavior, Animal
  • Disease Models, Animal
  • Female
  • Glycolipids / metabolism
  • Glycosphingolipids / metabolism*
  • Male
  • Mice
  • Mice, Knockout
  • Models, Genetic*
  • N-Acetylgalactosaminyltransferases / genetics
  • N-Acetylgalactosaminyltransferases / physiology*
  • Oligosaccharides / metabolism
  • Research Design
  • Sandhoff Disease / genetics
  • Sandhoff Disease / metabolism
  • Sandhoff Disease / therapy*
  • Substrate Specificity
  • beta-N-Acetylhexosaminidases / genetics
  • beta-N-Acetylhexosaminidases / physiology*

Substances

  • Glycolipids
  • Glycosphingolipids
  • Oligosaccharides
  • N-Acetylgalactosaminyltransferases
  • polypeptide N-acetylgalactosaminyltransferase
  • (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase
  • beta-N-Acetylhexosaminidases